Latest Contract Wins And Expansions News

Cyclopharm Limited is rapidly expanding its Technegas® lung imaging technology across the US, securing new contracts and advancing clinical guideline recognition that could boost adoption.

Monadelphous has reported a record-breaking year with $2.3 billion in new contracts and a strong financial performance, underpinned by strategic acquisitions and growth in energy transition sectors.

Resonance Health has revealed ambitious growth plans at its 2025 AGM, projecting revenue to nearly quadruple by FY26 while maintaining positive EBITDA guidance. The company is broadening its global footprint and diversifying its clinical trial services across multiple therapeutic areas.

Resonance Health reports robust FY25 results with 29% revenue growth and outlines ambitious FY26 guidance targeting $17 million in revenue and $2 million EBITDA. The company’s transformation into three profit-generating segments underpins its expanding footprint in the global clinical trial ecosystem.

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

NEXTDC has expanded its senior debt facilities to A$6.4 billion, enhancing financial flexibility to support rapid expansion driven by record contract wins and rising demand for AI and cloud infrastructure.

Acusensus has secured major contract expansions across Australia and New Zealand, driving a 15.8% revenue increase in Q2 FY25 and bolstering its cash reserves to $30.3 million. The company’s strategic international push and innovative enforcement technologies position it for sustained growth.